<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Functional Remission Threshold Theory: Stop When Residual Active Disease Probability Is Low - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-29</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-29</p>
                <p><strong>Name:</strong> Functional Remission Threshold Theory: Stop When Residual Active Disease Probability Is Low</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the optimal duration of anti-PD-1 immunotherapy for melanoma, and whether it differs by depth of response, based on the following results.</p>
                <p><strong>Description:</strong> Durable control after discontinuing anti-PD-1 in metastatic melanoma depends on whether biologically active residual disease remains above a clinically relevant risk. A composite of anatomic response (CR/PR/SD), metabolic remission (FDG-PET complete metabolic response), molecular clearance (ctDNA negativity), and clinical risk modifiers (e.g., brain metastases, LDH) estimates residual disease probability. When this composite risk predicts sufficiently low off-therapy progression over the next 24 months (≈≤20% risk), stopping preserves long-term outcomes while avoiding cumulative immunotoxicity and cost.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>In PET-Stop (EA6192), patients who are PET-negative/biopsy-negative at 1 year and ctDNA-negative will achieve ≥85–90% 24-month EFS after stopping.</li>
                <li>Among PR patients who are PET non-CMR at 12 months but convert to CMR by 18 months, 24-month off-therapy PFS will be non-inferior (≤5% absolute difference) to those with CMR at 12 months.</li>
                <li>Adding ctDNA to PET CMR will reduce 24-month relapse among early stoppers by ≈5–10% relative to PET alone by filtering rare PET false negatives.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>A subset of radiographic SD with PET CMR and undetectable ctDNA at 12–18 months will sustain ≥70% 24-month off-therapy PFS, implying functional remission can supersede RECIST anatomy.</li>
                <li>Immune profiling (e.g., CyTOF signatures) will add incremental discrimination in PET-indeterminate cases, but the generalizability across platforms/assays is uncertain.</li>
                <li>In high-risk clinical modifiers (brain metastases, high LDH), PET CMR plus ctDNA negativity may still fall short of the 80% 24-month PFS stop threshold, necessitating a higher bar or extended therapy.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If PET CMR ± biopsy at 1 year fails to enrich for low relapse (e.g., ≥25% 24-month relapse despite ctDNA negativity), the composite threshold construct is invalid or threshold set too permissively.</li>
                <li>If continuation beyond PET CMR materially improves 3-year OS by >5% absolute compared with stopping, continued therapy confers survival benefit beyond avoiding earlier PFS events, challenging early stop.</li>
                <li>If brain metastases/LDH do not independently predict post-stop relapse after adjusting for PET/ctDNA and response depth, the clinical component of R_stop requires revision.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Relatlimab+nivolumab (anti-LAG-3+PD-1) and ipilimumab+nivolumab combination-specific stopping thresholds are not defined; toxicity and response depth profiles differ and may shift thresholds. <a href="../results/extraction-result-83.html#e83.2" class="evidence-link">[e83.2]</a> <a href="../results/extraction-result-81.html#e81.4" class="evidence-link">[e81.4]</a> <a href="../results/extraction-result-86.html#e86.2" class="evidence-link">[e86.2]</a> <a href="../results/extraction-result-127.html#e127.0" class="evidence-link">[e127.0]</a> </li>
    <li>Mucosal melanoma (e.g., PMME) exhibits distinct biology and responses; the stopping threshold may not transfer directly. <a href="../results/extraction-result-75.html#e75.0" class="evidence-link">[e75.0]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>